YAMN-92Homo sapiens (Human)Cancer cell line
Also known as: YAManashi-N-92, YAMN92
AI Summary
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_A080 |
|---|---|
| Species | Homo sapiens (Human) |
Disease Information
| Disease | B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3) |
|---|
DepMap Information
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Leu194Arg (c.581T>G) | Unspecified | - | PubMed=20575032 |
| Gene fusion | PBX1 | TCF3-PBX1, E2A-PBX1 | - | - | PubMed=29786757 |
Publications
Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.
Minegishi M., Iwamoto S., Sugita K., Inukai T.
J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).
Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
Sugita K., Hosoi H.
Int. J. Hematol. 108:312-318(2018).
Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression.
Sugita K.
Cell Death Dis. 8:e2857.1-e2857.11(2017).
A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.
Tada M., Moriuchi T., Sugita K.
Am. J. Hematol. 85:535-537(2010).